Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDTFlow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging.Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugatesLow-cost photodynamic therapy devices for global health settings: Characterization of battery-powered LED performance and smartphone imaging in 3D tumor modelsImaging and photodynamic therapy: mechanisms, monitoring, and optimization.Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer.Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.PuraMatrix encapsulation of cancer cells.Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cellsImage-Based Quantification of Benzoporphyrin Derivative Uptake, Localization, and Photobleaching in 3D Tumor Models, for Optimization of PDT ParametersImpact of treatment response metrics on photodynamic therapy planning and outcomes in a three-dimensional model of ovarian cancer.An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour modelsExploiting a bacterial drug-resistance mechanism: a light-activated construct for the destruction of MRSA.Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids.Cabozantinib Inhibits Photodynamic Therapy-Induced Auto- and Paracrine MET Signaling in Heterotypic Pancreatic Microtumors
P50
Q27324380-EC6482D1-7E3E-4192-A45B-531FF41A7F8CQ30446755-88AC3D25-4720-41C4-8518-6573564A3DB2Q30493602-9DFB232B-6FC8-4EE1-B727-040F9B692E7DQ30574141-9D6AAAF2-2B70-461A-B21F-5DBF6CDFB233Q33443634-E7741D50-235C-45B0-8663-82E5D6806E18Q33960755-2BDAEA28-F098-428B-9836-0D6F763ABCC0Q34166300-602FF4AB-E6DC-4E2F-9710-8E0720C13F8CQ34675562-F5C5BC0C-76A0-48EC-95C6-08D1B5939B48Q34676773-D9AB4631-0D5D-4CC3-A1B7-162260E1E3FBQ35153231-031E4099-E822-4238-8C69-4B6BE5DF8786Q35973340-E8C0D38F-CF19-4D62-95E6-5D8B324A123EQ36329641-E6A7509B-0C95-4B36-ADF0-0F2EEABB450EQ37197458-86506291-06F8-4D39-AB81-F72B70272E56Q37489267-7AE48184-4279-43AB-9405-D121577AC2C7Q53415888-BDCC9B20-2ED2-4046-8A3F-5F8609687ABCQ55220021-43B7ED26-D832-4ABE-8EB9-E96D48499B51Q96114794-205C6F2D-5316-480F-AEFF-018FD36DC2AA
P50
description
dermatologist
@en
onderzoeker
@nl
name
Tayyaba Hasan
@ast
Tayyaba Hasan
@en
Tayyaba Hasan
@es
Tayyaba Hasan
@nl
Tayyaba Hasan
@sl
type
label
Tayyaba Hasan
@ast
Tayyaba Hasan
@en
Tayyaba Hasan
@es
Tayyaba Hasan
@nl
Tayyaba Hasan
@sl
prefLabel
Tayyaba Hasan
@ast
Tayyaba Hasan
@en
Tayyaba Hasan
@es
Tayyaba Hasan
@nl
Tayyaba Hasan
@sl
P69
P214
P244
P106
P21
P214
P244
nr89016985
P31
P496
0000-0003-0871-6057
P734
P7859
lccn-nr89016985